Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update
17 mai 2021 16h01 HE
|
Oncocyte Corporation
-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer...
Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.
06 mai 2021 08h00 HE
|
Oncocyte Corporation
Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s...
Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17
04 mai 2021 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting
28 avr. 2021 16h31 HE
|
Oncocyte Corporation
IRVINE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
19 avr. 2021 08h00 HE
|
Oncocyte Corporation
Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the...
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
14 avr. 2021 09h02 HE
|
Oncocyte Corporation
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
10 avr. 2021 13h31 HE
|
Oncocyte Corporation
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional...
Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results
16 mars 2021 16h01 HE
|
Oncocyte Corporation
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection ...
Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types
16 mars 2021 08h00 HE
|
Oncocyte Corporation
Novel immuno-oncology algorithm may offer independent and incremental predictive value over current standard biomarkers in the clinic Data suggest that measuring the tumor microenvironment (TME) as a...